Mega Lifesciences PCL (BKK:MEGA)
Thailand
· Delayed Price · Currency is THB | Market Cap | 30.95B |
| Revenue (ttm) | 14.19B |
| Net Income (ttm) | 1.91B |
| Shares Out | 871.87M |
| EPS (ttm) | 2.19 |
| PE Ratio | 16.19 |
| Forward PE | 13.28 |
| Dividend | 1.60 (4.51%) |
| Ex-Dividend Date | Mar 9, 2026 |
| Volume | 500,195 |
| Average Volume | 685,502 |
| Open | 35.25 |
| Previous Close | 35.50 |
| Day's Range | 34.75 - 35.25 |
| 52-Week Range | 24.30 - 40.00 |
| Beta | 0.33 |
| RSI | 54.25 |
| Earnings Date | May 14, 2026 |
About Mega Lifesciences PCL
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It offers wellness and nutrition products, including medical and sports nutrition, general well-being, vitamins, probiotics, herbal medicines, and cough and cold medicines, as well as hair, kid’s, men’... [Read more]
Financial Performance
In 2025, Mega Lifesciences PCL's revenue was 14.19 billion, a decrease of -7.74% compared to the previous year's 15.39 billion. Earnings were 1.91 billion, a decrease of -4.99%.
Financial StatementsNews
Mega Lifesciences PCL Earnings Call Transcript: Q4 2025
FY 2025 saw revenue decline narrow to 7.8% YoY, with branded business growing 4.3% and distribution recovering in 2H. Gross margin improved, and EBITDA rose 2.6% YoY. FY 2026 revenue is guided to grow 8-12%, led by branded business and Myanmar recovery.
Mega Lifesciences PCL Earnings Call Transcript: Q3 2025
Nine-month 2025 revenue reached THB 10.4 billion, with branded business growing 4.3% YoY and distribution stabilizing. Q3 net profit rose 29.1% YoY, and the company expects low double-digit branded growth and stable dividends, while investing in new manufacturing facilities.
Mega Lifesciences PCL Earnings Call Transcript: Q2 2025
Strategic focus on brand and product development is supported by a five-year growth plan, with higher second-half revenue and stable profitability expected. CapEx is concentrated in Indonesia and Vietnam, and internal cash flow is projected to cover investments and debt.
Mega Lifesciences PCL Earnings Call Transcript: Q1 2025
Q1 2025 revenue fell 14.1% due to Myanmar distribution decline, but branded business grew 2.8% and gross margins improved. Strong performance in Africa and other markets, ongoing expansion in Indonesia and Vietnam, and a stable net cash position support a positive outlook despite Myanmar and tax headwinds.
Mega Lifesciences PCL Transcript: AGM 2025
Revenue and profits remained flat in 1H and 2Q 2024, with branded and Pharma businesses showing growth while distribution and consumer segments in Myanmar declined. Strategic expansion continues in Southeast Asia and Africa, with a robust product pipeline and focus on operational efficiency.
Mega Lifesciences PCL Earnings Call Transcript: Q4 2024
Approval for a major Vietnam project reduces political risk, while focus shifts to monoclonal antibody and new product launches. Annual growth targets of 27–28% are set, with internal accruals expected to fund expansion.
Mega Lifesciences PCL Earnings Call Transcript: Q2 2024
Revenue and net profit were flat YoY in 1H24, with improved gross margins offset by higher SG&A. Branded business is growing, driven by pharma, while distribution faces headwinds in Myanmar. Outlook for 2024 is 5-6% growth, with potential for 8-10% in 2025, supported by new product launches.